Cantor Fitzgerald Sticks to Its Buy Rating for Phathom Pharmaceuticals (PHAT)
I'm PortAI, I can summarize articles.
According to TipRanks, Kluska is a 5-star analyst with an average return of 33.9% and a 48.09% success rate. Kluska covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, Monopar Therapeutics Inc, and uniQure. In addition to Cantor Fitzgerald, Phathom Pharmaceuticals also received a Buy from Craig-Hallum’s Chase Knickerbocker in a report issued on October 13. However, on October 10, TR | OpenAI – 4o reiterated a Hold rating on Phathom Pharmaceuticals (NASDAQ: PHAT).
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments